Ukraine's Zelenskiy says Turkey is a partner in security guarantees
U.S. to install senior diplomat as chargé to oversee China embassy: State Dept
World's top electronics maker Foxconn Q4 profit drops 13%
US and Israel look to Africa for resettling Palestinians uprooted from Gaza, AP reports
Japan PM apologises for giving out gifts, clouding budget prospects
Millions of people celebrate Holi, the Hindu festival of colors
Olympics-Olympians make climate plea to IOC presidential candidates
Airlines that have updated their lithium battery policies
BRUSSELS (Reuters) - Europe's top court should back U.S. gene sequencing company Illumina's appeal against the EU antitrust regulators' review of its $7.1 billion bid for cancer test maker Grail, an adviser to the court said on Thursday.
A lower tribunal in 2022 had sided with the European Commission, prompting Illumina to take its case to the Luxembourg-based Court of Justice of the European Union (CJEU).
CJEU Advocate General Nicholas Emiliou said judges should set aside the General Court judgment and annul Commission decisions on referral request.
Judges usually follow such non-binding opinions in the majority of cases.
The case is C-625/22 P - Grail v Commission and Illumina.
(Reporting by Foo Yun Chee; Editing by Sudip Kar-Gupta)
